Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Current Liabilities (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Total Current Liabilities for 10 consecutive years, with $105.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 8.29% to $105.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $105.9 million, a 8.29% decrease, with the full-year FY2025 number at $105.9 million, down 8.29% from a year prior.
  • Total Current Liabilities was $105.9 million for Q4 2025 at Rhythm Pharmaceuticals, up from $104.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $129.5 million in Q2 2025 to a low of $16.8 million in Q1 2021.
  • A 5-year average of $61.8 million and a median of $48.7 million in 2022 define the central range for Total Current Liabilities.
  • Biggest YoY gain for Total Current Liabilities was 180.56% in 2022; the steepest drop was 8.33% in 2022.
  • Rhythm Pharmaceuticals' Total Current Liabilities stood at $43.4 million in 2021, then fell by 8.33% to $39.8 million in 2022, then surged by 38.67% to $55.2 million in 2023, then surged by 109.26% to $115.5 million in 2024, then dropped by 8.29% to $105.9 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Total Current Liabilities are $105.9 million (Q4 2025), $104.3 million (Q3 2025), and $129.5 million (Q2 2025).